Scott Kay, pharmaceuticals analyst at Bank of America Securities, says this could help Merck maintain its share of the U.S. cholesterol market.

FORBES: For Merck, Steps In The Right Direction

Scott Kay at Banc of America Securities and Anthony Butler at Lehman Brothers both expect a positive decision, but their sales estimates for the drug differ.

FORBES: Unleashing Pharma's Dogs

Scott Kay, the pharmaceutical analyst at Banc of America Securities, wrote in a note to investors that while Bristol still faces a basketful of problems, the additional delay is not cause for additional worry.

FORBES: Bristol's Big Tease